Skip to main content

Advertisement

SpringerLink
Log in

Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Previous studies analyzing lipid profile in small cohorts of patients with rheumatic and inflammatory bowel diseases (IBD) treated with TNFα blockers showed conflicting results. We aim to evaluate the effect of anti-TNFα monoclonal antibodies, infliximab and adalimumab, on lipid profile in IBD patients followed up to 3 years.

Methods

Clinical charts of 128 consecutive IBD patients, who received at least three doses of infliximab or two doses of adalimumab, and with a clinical follow-up of at least 1 year, were retrospectively reviewed. Lipid profiles (total, HDL and LDL cholesterol, and triglycerides) before beginning the treatment and after 1 and 3 years of follow-up were collected. Multiple linear regression analysis was performed considering total cholesterol difference at basal time, 1 and 3 years as a dependent variable.

Results

There was not a statistically significant difference between pre- and post-treatment lipid profiles. However, the subgroup with normal-range total cholesterol level before anti-TNFα treatment (n = 82) showed a significant increase in total cholesterol after 1 and 3 years, and a significant increase in LDL cholesterol after 3 years. The subgroup with basal normal-range triglycerides showed a significant increase after 1 and 3 years of follow-up. Atherogenic index resulted significantly increased after 3 years of anti-TNFα treatment. Multivariate analysis showed no influence of age, gender, type of IBD, body mass index, or the presence of two or more cardiovascular risk factors.

Conclusions

No significant changes in lipid profile of IBD patients on anti-TNFα therapy were observed after 1 and 3 years of treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis. 2005;64:303–305.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  2. Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis. 2007;66:1503–1507.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. J Rheumatol. 2006;33:2440–2446.

    CAS  PubMed  Google Scholar 

  4. Antoniou C, Dessinioti C, Katsambas A, Stratigos AJ. Elevated triglyceride and cholesterol levels after intravenous antitumour necrosis factor-alpha therapy in a patient with psoriatic arthritis and psoriasis vulgaris. Br J Dermatol. 2007;156:1090–1091.

    Article  CAS  PubMed  Google Scholar 

  5. Castro KR, Aikawa NE, Saad CG, et al. Infliximab induces increase in triglyceride levels in psoriatic arthritis patients. Clin Dev Immunol. 2011;2011:352686.

    PubMed Central  PubMed  Google Scholar 

  6. Sappati Biyyani RS, Putka BS, Mullen KD. Dyslipidemia and lipoprotein profiles in patients with inflammatory bowel disease. J Clin Lipidol. 2010;4:478–482.

    Article  PubMed  Google Scholar 

  7. Koutroubakis IE, Oustamanolakis P, Malliaraki N, et al. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2009;21:283–288.

    Article  CAS  PubMed  Google Scholar 

  8. Parmentier-Decrucq E, Duhamel A, Ernst O, et al. Effects of infliximab therapy on abdominal fat and metabolic profile in patients with Crohn’s disease. Inflamm Bowel Dis. 2009;15:1476–1484.

    Article  PubMed  Google Scholar 

  9. Nunes T, Etchevers MJ, Merino O, et al. Does smoking influence Crohn’s disease in the biologic era? The TABACROHN study. Inflamm Bowel Dis. 2013;19:23–29.

    Article  PubMed  Google Scholar 

  10. Dorn SD, Sandler RS. Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. Am J Gastroenterol. 2007;102:662–667.

    Article  PubMed  Google Scholar 

  11. Bewtra M, Kaiser LM, TenHave T, Lewis JD. Crohn’s disease and ulcerative colitis are associated with elevated standardized mortality ratios: a meta-analysis. Inflamm Bowel Dis. 2013;19:599–613.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death—a Danish nationwide cohort study. PLoS ONE. 2013;8:e56944.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Fumery M, Xiaocang C, Dauchet L, Gower-Rousseau C, Peyrin-Biroulet L, Colombel JF. Thromboembolic events and cardiovascular mortality in inflammatory bowel diseases: a meta-analysis of observational studies. J Crohns Colitis. 2014;8:469–479.

    Article  PubMed  Google Scholar 

  14. Singh S, Singh H, Loftus EV Jr, Pardi DS. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:382–393.

    Article  PubMed  Google Scholar 

  15. Principi M, Mastrolonardo M, Scicchitano P, et al. Endothelial function and cardiovascular risk in active inflammatory bowel diseases. J Crohns Colitis. 2013;7:e427–e433.

    Article  PubMed  Google Scholar 

  16. Menchen L, Marin-Jimenez I, Arias-Salgado EG, et al. Matrix metalloproteinase 9 is involved in Crohn’s disease-associated platelet hyperactivation through the release of soluble CD40 ligand. Gut. 2009;58:920–928.

    Article  CAS  PubMed  Google Scholar 

  17. Nagahori M, Hyun SB, Totsuka T, et al. Prevalence of metabolic syndrome is comparable between inflammatory bowel disease patients and the general population. J Gastroenterol. 2010;45:1008–1013.

    Article  CAS  PubMed  Google Scholar 

  18. Tracey KJ, Wei H, Manogue KR, et al. Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation. J Exp Med. 1988;167:1211–1227.

    Article  CAS  PubMed  Google Scholar 

  19. Fong Y, Moldawer LL, Marano M, et al. Cachectin/TNF or IL-1 alpha induces cachexia with redistribution of body proteins. Am J Physiol. 1989;256:R659–R665.

    CAS  PubMed  Google Scholar 

  20. Ericsson S, Eriksson M, Vitols S, Einarsson K, Berglund L, Angelin B. Influence of age on the metabolism of plasma low density lipoproteins in healthy males. J Clin Invest. 1991;87:591–596.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Ericsson S, Berglund L, Frostegard J, Einarsson K, Angelin B. The influence of age on low density lipoprotein metabolism: effects of cholestyramine treatment in young and old healthy male subjects. J Intern Med. 1997;242:329–337.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

Supported by Grants from Spanish Ministry of Health (Instituto de Salud Carlos III-ISCIII-FIS 10/01912 and CIBEREHD) to LM.

Conflict of interest

The authors declare that they have no conflict of interest, financial or otherwise, with respect to this work.

Author information

Authors and Affiliations

  1. Sección de Gastroenterología, Servicio de Aparato Digestivo, Hospital General Universitario “Gregorio Marañón” - Instituto de Investigación Sanitaria Gregorio Marañón, C/Dr. Esquerdo 46, 28007, Madrid, Spain

    José Miranda-Bautista, Celia de Gracia-Fernández, María López-Ibáñez, Alejandra Gallo-Moltó, Marina González-Arias, Casilda González-Gil, Ignacio Marín-Jiménez & Luis Menchén

  2. Medicina Interna, Hospital General Universitario Gregorio Marañón - Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

    María Barrientos

  3. Medicina Preventiva, Hospital General Universitario Gregorio Marañón - Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain

    Alicia Díaz-Redondo

  4. Centro de Investigación en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Instituto de Salud Carlos III, Madrid, Spain

    Luis Menchén

  5. Departamento de Medicina, Universidad Complutense de Madrid, Madrid, Spain

    Luis Menchén

Authors
  1. José Miranda-Bautista
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Celia de Gracia-Fernández
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. María López-Ibáñez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. María Barrientos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Alejandra Gallo-Moltó
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Marina González-Arias
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Casilda González-Gil
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alicia Díaz-Redondo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ignacio Marín-Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Luis Menchén
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Luis Menchén.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miranda-Bautista, J., de Gracia-Fernández, C., López-Ibáñez, M. et al. Lipid Profile in Inflammatory Bowel Disease Patients on Anti-TNFα Therapy. Dig Dis Sci 60, 2130–2135 (2015). https://doi.org/10.1007/s10620-015-3577-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-015-3577-0

Keywords

Search

Navigation